BEMCX
Price
$8.44
Change
+$0.02 (+0.24%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

BEMCX vs RNWFX

Header iconBEMCX vs RNWFX Comparison
Open Charts BEMCX vs RNWFXBanner chart's image
Brandes Emerging Markets Value C
Price$8.44
Change+$0.02 (+0.24%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
BEMCX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
BEMCX vs. RNWFX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEMCX is a Hold and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. BEMCX (634M). RNWFX pays higher dividends than BEMCX: RNWFX (1.51) vs BEMCX (1.22). BEMCX was incepted earlier than RNWFX: BEMCX (12 years) vs RNWFX (23 years). RNWFX is a more actively managed with annual turnover of: 32.00 vs. BEMCX (19.23). RNWFX has a lower initial minimum investment than BEMCX: RNWFX (250) vs BEMCX (2500). BEMCX annual gain was more profitable for investors over the last year : 6.52 vs. RNWFX (5.86). RNWFX return over 5 years is better than : 14.39 vs. BEMCX (-0.53).
BEMCXRNWFXBEMCX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years23 years-
Gain YTD3.8854.54985%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRAN/AN/A-
Net Assets634M62.2B1%
Annual Yield % from dividends1.221.5181%
Returns for 1 year6.525.86111%
Returns for 3 years6.73-5.10-132%
Returns for 5 years-0.5314.39-4%
Returns for 10 years17.4242.6741%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics